The CDC recently updated RSV vaccine recommendations to include certain adults aged 50 and up. When is the best time to get ...

The COVID booster currently available is based on the JN.1 subvariant. Nimbus is a direct descendant of JN.1 – as is another ...

The FDA has accepted for review the sBLA to expand the indication of Arexvy (RSV vaccine, adjuvanted) to adults aged 18 to 49 years who are at increased risk.

GSK announces US FDA accepts application to review expanded use of RSV vaccine, Arexvy for adults 18-49 at increased risk: London, UK Wednesday, July 16, 2025, 14:00 Hrs [IST] GSK ...

The usually sluggish FTSE 100 is having a surprisingly good year. But our writer feels there are still potential bargains ...

Pharmaceutical Technology serves as the connection to bio manufacturing and development, featuring regulatory updates and expert industry news.

RSV has outstripped severe Covid and flu hospitalisation rates and proved itself more fatal than either of the flu season ...

Not content with taking on the respiratory syncytial virus (RSV) prevention market with its antibody-based therapy Beyfortus, AstraZeneca has agreed to buy US biotech Icosavax and its phase 3 ...

MSD's phase 2b/3 data with clesrovimab for RSV prevention in infants sets up a challenge to Sanofi and AstraZeneca's fast-growing Beyfortus.

Residents in public residential aged care services aged 60 and over can now claim a free vaccine for Respiratory Syncytial ...

The Indiana Department of Health is hosting the 39th Annual Indiana Health Fair this weekend, offering Hoosiers access to ...